No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 2.7x · 10Y median 4.9x · 38th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 26
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:26:08.343Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T16:26:08.343Z. Latest historical point 2023-08-14.
The latest delayed quote for Celularity Inc. (CELU) stock was $1.76 as of Oct 6, 2026, 12:20 PM EDT, up 2.63% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -19.6% · 3-year avg -6.8%/yr · 5-year avg -52.6%/yr
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources.
Biotechnology · Florham Park, NJ
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-2.70
vs Estimate
$-0.30
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CELU | $50.80M | $1.75 | +2.63% | -19.63% | -52.57% | N/A | N/A |
| 2CLNN | $50.73M | $3.97 | +1.53% | -62.62% | -51.16% | N/A | vs CELU |
| 3COCH | $50.96M | $0.66 | +1.40% | -19.94% | -41.73% | N/A | vs CELU |
| 4INMB | $50.51M | $1.90 | -2.06% | -6.70% | -36.88% | N/A | vs CELU |
| 5ELOX | $51.13M | $14.88 | -3.44% | N/A | N/A | N/A | vs CELU |
| 6MBOT | $50.36M | $1.10 | +3.27% | -64.98% | -31.63% | -39.57% | vs CELU |
forward FY estimate
N/A
$3.85M
vs Estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.75
High
N/A
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.75 | $-2.75 | $-2.75 | 1 |
| FY 2027 | $1.50 | $1.50 | $1.50 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $44.00M | $44.00M | $44.00M | 1 |
| FY 2027 | $285.66M | $285.66M | $285.66M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
